Humanin.

Humanin is a research compound in the mitochondrial & longevity peptides.

Mitochondria-derived peptides studied in metabolism and stress responses.

It draws interest for mitochondrial & longevity peptides.

F-tier evidence: human evidence is limited; most support is preclinical.

What it is

Humanin is a 24-amino-acid mitochondrial-derived peptide (MDP), one of the first members of a class of small peptides encoded by short open reading frames within the mitochondrial genome rather than the nuclear genome. Its coding sequence sits inside the mitochondrial 16S ribosomal RNA region (MT-RNR2), and a near-identical nuclear-encoded form also exists. It was discovered in 2001 by Hashimoto and colleagues in Ikuo Nishimoto's lab at Keio University during a cDNA screen for factors that protected neurons from Alzheimer's-disease-related insults, and it is studied primarily as a cytoprotective and metabolic signaling peptide.

How it works

Humanin acts both intracellularly and as a secreted, receptor-mediated factor. Intracellularly it binds and antagonizes the pro-apoptotic Bcl-2-family proteins BAX, tBID and BimEL, blocking their translocation to mitochondria and suppressing apoptosis. Extracellularly it signals through a tripartite cytokine-like receptor complex (CNTF receptor / WSX-1 / gp130) that activates STAT3, and also engages formyl-peptide receptors (FPRL1/FPR2). It modulates insulin/IGF-1 signaling—interacting with IGFBP-3 and enhancing AKT phosphorylation—and acts centrally in the hypothalamus as an insulin sensitizer; the engineered S14G analog (HNG) is far more potent than the native peptide in preclinical assays.

What the evidence shows

The strongest data are preclinical. In cell and rodent models, humanin and HNG reduce neuronal death from amyloid-beta and other insults, shrink infarct size in stroke models, improve glucose handling, and reduce age-related cognitive decline in mice (Yen et al., Scientific Reports 2018; Hashimoto et al., J Neurosci 2001). Human evidence is observational, not interventional: circulating humanin declines with age, is lower in conditions such as Alzheimer's disease and the mitochondrial disorder MELAS, and higher levels have been associated with better "cognitive age" and with longevity-enriched cohorts (long-lived offspring, centenarians). Critically, there are no published randomized controlled trials of exogenous humanin or HNG in humans, and no completed published Phase 1 safety trial—so therapeutic benefit in people remains unproven and the human-versus-animal gap is large.

Safety considerations

Because no controlled human trials of administered humanin or HNG have been completed and published, the human safety profile is essentially unknown, including immunogenicity, dosing tolerability, and long-term effects. As a STAT3-activating, anti-apoptotic and growth-signaling peptide, theoretical concerns include effects on cell survival and proliferation pathways, but these have not been characterized clinically. Material sold online as "humanin" is research-use-only chemical of unverified identity and purity, not a pharmaceutical product, adding contamination and mislabeling risks. No safety conclusions for human use can be drawn from the existing animal and cell data.

Regulatory status

Humanin and its analog HNG are not approved by the FDA, EMA, or any major regulator for any indication; they are investigational/research-use-only compounds with no completed published Phase 1 human trial. They are not established WADA-prohibited substances by name, but exogenous peptides with growth-factor-like signaling can fall under broad anti-doping categories—status should not be assumed.

1. [1]Detailed characterization of neuroprotection by a rescue factor humanin against various Alzheimer's disease-relevant insults — Journal of Neuroscience, 2001, PMID 11717357 (Hashimoto Y et al.)
2. [2]The emerging role of the mitochondrial-derived peptide humanin in stress resistance — Journal of Molecular Endocrinology, 2013, PMID 23239898 (Yen K et al.)
3. [3]Humanin Prevents Age-Related Cognitive Decline in Mice and is Associated with Improved Cognitive Age in Humans — Scientific Reports, 2018, PMID 30242290 (Yen K et al.)
4. [4]The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan — Aging (Albany NY), 2020, PMID 32575074 (Yen K et al.)

• Not FDA-approved; research-only.
• Human evidence is minimal; longevity claims are preclinical.

Stack fit

Why not D: held back by human evidence, safety clarity, regulatory clarity, practical relevance.

What would move it up: Larger controlled human trials, clearer long-term safety, replicated findings, and regulatory progress.

What would move it down: Failed confirmatory trials, new safety signals, or evidence that popular claims don't translate.

• Humanin is not FDA-approved for human use; it is discussed in a research context.
• It belongs to the Mitochondrial & longevity peptides class.
• Its principal mechanism is characterized in the literature.

• Whether observed effects reliably translate to humans at large.
• Long-term safety in healthy users, and full drug-interaction risk.
• Optimal studied parameters outside any approved indication.
• Claim-by-claim verdicts — these are authored against verified sources and shown when complete.
• Quality and purity of material from non-pharmaceutical sources.

1. What it is
2. The Mitochondrial peptide signalling mechanism
3. The preclinical evidence lane
4. Why Preliminary, and not higher or lower
5. Proven lane vs speculative lane
6. What people report
7. Regulatory status
8. What changed recently